Genezen Licenses Cytegrity Stable Lentivirus Production System from CSL

Will offer its clients immediate access to cutting edge technology for stable and scalable high-titer clinical lentivirus production.

Author Image

By: Charlie Sternberg

Associate Editor

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has licensed the Cytegrity proprietary stable production system from biotechnology company CSL.   Cytegrity is an advanced inducible stable producer technology designed for the production of lentiviral vectors (LVVs). This technology is designed to allow for scalable and cost-effective generation of LVVs at clinically effective titers for both gene and cell therapies.   Lentiviral vectors are traditi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters